Cognitive Strategies for Weight Loss
The Miriam Hospital · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Brown University · NCT05799846
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–70 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 360
- US sites recruiting
- 1
- Study start
- March 1, 2023
- Record last updated
- July 15, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to compare weight change and other related outcomes associated with three different behavioral weight loss interventions (STANDARD Behavioral, PREVENT, and PROMOTE) in adults with obesity. The main questions it aims to answer are:
- Which of the three Internet-delivered weight loss programs results in the greatest weight loss?
- How do key weight-related behaviors (e.g., adherence, diet, physical activity) differ across the arms?
- What individual characteristics predict success in each arm?
- What are the underlying mechanisms of each approach?
- Are there any potential adverse outcomes associated with any of the conditions (e.g., depression, weight stigmatization, increased body image concerns).
Participants will
- signed informed consent
- complete a baseline assessment
- be randomized to 12 months of either Standard iBWL, PREVENT or PROMOTE
- complete a training workshop to learn arm-specific cognitive strategies
- complete a 12-month Internet-delivered weight loss program, requiring self-monitoring of intake and exercise and viewing of 12 weekly lessons followed by 9 monthly lessons
- complete an assessment at 3 months (during treatment)
- complete a refresher workshop on arm-specific cognitive strategies at 3 months
- complete an assessment at 6 months (during treatment), 12 months (at the conclusion of treatment), and 18 months (6 months after treatment
Being studied: Standard Behavioral Weight Loss Intervention; PREVENT Behavioral Weight Loss Intervention; PROMOTE Behavioral Weight Loss Intervention
Conditions: Obesity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Participants will be between the ages of 18 and 70, have a BMI between 25 and 45 kg/m2, and have regular (i.e., weekly) access to the Internet, defined as owning a smart phone with Internet capabilities, and/or having a broadband or Wi-Fi connection at home or work.
Exclusion Criteria
- Exclusionary criteria include: 1) current enrollment in a weight loss program, 2) currently taking weight loss medications, 3) history of bariatric surgery or planned bariatric surgery in the next 18 months, 4) individuals who are pregnant, nursing, or have plans to become pregnant within the next 18 months, 5) individuals planning to relocate outside the area in the next 18 months, 6) any medical condition for which weight loss would be contraindicated, 7) neurological or psychiatric conditions including but not limited to schizophrenia and bipolar disorder, 8) inability to attend assessments at the Weight Control and Diabetes Research Center in Providence, RI.
Individuals with mobility issues, dizziness, or history of heart disease, diabetes, or cancer will be required to provide physician consent prior to enrolling.
Recruiting US locations
Weight Control & Diabetes Research Center
Providence, RI 02903
Site contact: Kathryn E Demos McDermott, PhD · 4017938939 · kathryn_demos@brown.edu
Similar studies in Rhode Island
All weight loss studies in Rhode Island →- RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
- Location
- Providence, RI + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company
- Location
- Providence, RI + 34 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Amgen
- Location
- East Greenwich, RI + 30 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen
- Location
- East Greenwich, RI + 69 other US sites
- Eligibility basics
- Ages 18–99